Search the Newsreel

Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026

Compass Pathways plc (Nasdaq: CMPS) announced its participation in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026, where management will hold a fireside chat. Additionally, the company will attend the Stifel Biotech Summit on August 10, 2026. Both events will have live …

UiPath Announces Second Quarter Fiscal 2027 Financial Results Conference Call

NEW YORK, August 06, 2026--(BUSINESS WIRE)--UiPath (NYSE: PATH), a leader in business orchestration and automation, today announced it will report financial results for its second quarter fiscal 2027 ended July 31, 2026 after the market closes on Thursday, September 3, 2026. Management will host …

Compass Pathways partners with VA on psilocybin trial for veterans

Compass Pathways is collaborating with the U.S. Department of Veterans Affairs on a multi-site clinical trial for their COMP360 psilocybin treatment for veterans with treatment-resistant depression, including those with PTSD. The "PIVOT" study will evaluate different doses of COMP360, a synthetic psilocybin formulation, across …

CEO Kabir Nath has shares withheld for taxes at COMPASS Pathways (CMPS)

COMPASS Pathways CEO Kabir Nath reported an insider transaction where 5,962 Ordinary Shares were withheld by the issuer on August 3, 2026, to cover tax withholding obligations upon the vesting of restricted share units. These shares were valued at $11.25 per share and were …

Explore AI Communications Growth: Pathos Communications (LSE:NEWS) in Focus

Earnings call transcript: COMPASS Pathways advances q2 2026 launch plans as stock slips

COMPASS Pathways reported $433 million in cash as of June 30, sufficient to fund operations through launch and into 2028, and is progressing with its NDA submission for COMP360, a psilocybin treatment for depression. Despite positive Phase III data and advancing commercial preparations, the …

RBC Adjusts PT on COMPASS Pathways to $21 From $22, Maintains Outperform Speculative Risk Rating

RBC has revised its price target for COMPASS Pathways (CMPS) down to $21 from $22, while continuing to maintain an "Outperform Speculative Risk" rating on the stock. This adjustment comes amidst recent news for the biotechnology company, including other analyst rating changes and financial …

Pathos Communications hails "record" trading month in July

Cavendish sticks with 42p target as Pathos shares recover ground

Pathos Communications hails record July performance

B. Riley Financial Forecasts Strong Price Appreciation for Compass Pathways (NASDAQ:CMPS) Stock

Pathos Communications reports record monthly revenue in July By Investing.com

Pathos Communications PLC Reports Unaudited Revenue Results for the Month of July 2026

Compass Pathways (Nasdaq: CMPS) grows cash to $433M as COMP360 trials succeed

Compass Pathways plc reported a net loss of $162.6 million for the first six months of 2026, largely due to non-cash warrant liabilities and increased administrative spending, yet saw its cash and cash equivalents grow to $433.3 million. This financial boost was driven by …

UiPath (PATH) Registers a Bigger Fall Than the Market: Important Facts to Note

UiPath (PATH) ended the recent trading session at $13.82, demonstrating a -1.99% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.17%. Meanwhile, the Dow gained 0.49%, and the Nasdaq, a tech-heavy index, lost 0.83%. Shares of …

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON & NEW YORK, August 05, 2026--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen …

Oppenheimer reiterates Compass Pathways stock rating on FDA progress By Investing.com

Oppenheimer has reaffirmed its Outperform rating and $20.00 price target for Compass Pathways (NASDAQ:CMPS) following the company's Q2 2026 update, which bolstered confidence in its psilocybin-based therapy, COMP360. Compass Pathways holds $433 million in cash, providing runway into 2028, and is progressing towards potential …

Compass Pathways (NASDAQ:CMPS) Announces Earnings Results, Misses Expectations By $1.49 EPS

COMPASS Pathways Q2 2026 Loss Widens 358.5% Beyond Estimates

COMPASS Pathways plc (NASDAQ:CMPS) reported a Q2 2026 loss of $1.88 per share, significantly wider than the estimated $0.41, representing a 358.5% miss. Despite the substantial net loss of $253.8M, the stock rallied 4.9%, indicating investor focus on clinical development milestones over immediate financial …

COMPASS Pathways (CMPS) Is Up 8.8% After Q2 Net Loss Surges To US$254 Million – Has The Bull Case Changed?

COMPASS Pathways reported a significant net loss of US$253.79 million in Q2 2026, a sharp increase from the previous year, with losses per share at US$1.88. This surge in expenses comes as the company remains pre-revenue, intensifying focus on its ability to fund the …

COMPASS PATHWAYS ($CMPS) Releases Q2 2026 Earnings

This article first appeared on GuruFocus. Cash Position: $433 million in cash on hand as of June 30, 2026, expected to fund operations through launch and into 2028. Regulatory Milestone: Rolling NDA submission for COMP360 in treatment-resistant depression (TRD) underway; completion expected in the …

COMPASS Pathways plc Q2 2026: Revenue $0 Net loss $253.8M, EPS $(1.88) — 10-Q Summary

COMPASS Pathways plc reported a net loss of $253.8M, or diluted loss per share of $(1.88), for Q2 2026, with no product revenue as it remains a clinical-stage company. The company achieved positive primary endpoints in Phase 3 trials for treatment-resistant depression and advanced …

Compass Pathways (Nasdaq: CMPS) posts $253.8M Q2 loss and builds COMP360 launch

Compass Pathways reported a Q2 2026 net loss of $253.8 million, largely due to a non-cash loss from warrant liabilities, compared to $38.4 million in Q2 2025. Despite the widened loss, the company is making significant progress with its COMP360 psilocybin treatment for treatment-resistant …

Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Data from two positive Phase 3 trials demonstrated rapid onset of effect and durable benefit through at least 6 months, further validating COMP360's potential to establish a new standard of care in TRD COMP360 has a highly differentiated clinical profile and is expected to …

Progressive Path Group Holdings Ltd. Revenue Breakdown – HKEX:1581

Compass Pathways Launches Proposed $150.0 Million Public Offering

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company focused on mental health innovation, has announced a proposed public offering of $150.0 million in American Depositary Shares (ADSs) and pre-funded warrants. The company may also grant underwriters an option to purchase an additional $22.5 million …

Palantir Rockets 16% After Q2 Blowout; C3.ai, UiPath Sit Out the Rally

Quick Read Palantir's Q2 revenue surged 93% to $1.94 billion, beating consensus, with U.S. commercial total contract value hitting a record $2.1 billion. PLTR rocketed 16% while AI and PATH caught zero sympathy bid, confirming this as a pure single-stock reaction to earnings. Palantir …

CMPS Stock Clocks Muted Gains But Analysts Back Psychedelic Drug’s Durability Ahead Of FDA Filing

Compass Pathways PLC (CMPS) saw muted stock gains despite announcing positive 26-week data from its COMP360 trial for treatment-resistant depression, which confirmed the drug's rapid onset and durability. Analysts maintained "Buy" or "Outperform" ratings, emphasizing the long-term market opportunity and the drug's clean safety …

Compass Pathways PLC expected to post a loss of 40 cents a share - Earnings Preview

Compass Pathways PLC (CMPS) is projected to report a loss of 40 cents per share in its upcoming earnings announcement. This information is derived from a Refinitiv earnings preview. The full article can be accessed on TradingView, which aggregates news from various sources including …

Seven Fleet Capital Management LP Buys 118,021 Shares of Compass Pathways PLC Sponsored ADR $CMPS

Vanguard Capital Management (LPTH) reports 3.1M LightPath Technologies shares on Schedule 13G/A

Vanguard Capital Management has reported a beneficial ownership of 3,095,887 shares of LightPath Technologies Inc. (LPTH) common stock, representing 4.66% of the class as of June 30, 2026. This disclosure was made on a Schedule 13G/A filing, indicating a passive investment where Vanguard holds …

Price to book forward of Pathfinder Bancorp, Inc. – NASDAQ:PBHC

This article briefly mentions the "Price to book forward" for Pathfinder Bancorp, Inc. (NASDAQ: PBHC). It provides the company's ticker, the exchange it trades on, and states that the market was closed with no trades. The content appears to be a stub or a …

Zephyr Energy, Critical Mineral Resources, Tooru, Quantum Blockchain, Ilika, Pathos Communications

Zephyr Energy PLC (AIM:ZPHR, OTCQB:ZPHRF, FRA:VD5N) has landed a letter of intent for up to $15 million to fund the Paradox Project. CEO Colin Harrington says it gives Zephyr options, letting them develop alone or bring in a partner. Critical Mineral Resources PLC (LSE:CMRS, …

Pathfinder Bancorp shifts liquidity into securities as net income reaches $2.7M

Pathfinder Bancorp reported a net income of $2.7 million, or $0.42 per diluted share, for Q2 2026, marking a significant increase from previous periods. The company strategically shifted underutilized liquidity into available-for-sale securities, contributing to sequential growth in net interest income. Despite a decrease …

Pathfinder Bancorp, Inc. Announces Financial Results for the Second Quarter of 2026

Pathfinder Bancorp, Inc. reported net income of $2.7 million, or $0.42 per diluted share, for the second quarter of 2026, a significant improvement from previous periods. The company attributed this growth to stable credit performance, disciplined loan and deposit pricing, and strategic deployment of …

Pathfinder Bancorp net income surges to $2.7M in Q2FY26

Pathfinder Bancorp, Inc. reported a significant increase in net income for Q2FY26, reaching $2.7 million ($0.42 per diluted share), a substantial rise from $31,000 in the prior year, driven by strategic asset reallocation and effective credit risk management. The bank saw a sequential increase …